sorfequiline

Phase 2

GGlobal Alliance for TB Drug Development

sorfequiline is one of 8 therapeutic programs targeting Tuberculosis, Pulmonary. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Tuberculosis, PulmonaryNot yet recruiting

Pulmonary TBActive, not recruiting

Tuberculosis, PulmonaryPhase 2

Not yet recruiting

Pulmonary TBPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Pulmonary TB

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Phase 2

2 2

Zyvox

Pfizer

Phase 2

1 3

Sirturo

WWim Janssens

Phase 2

2 4

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 5

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

Deltyba

Otsuka

Phase 2

1 7

sorfequiline

GGlobal Alliance for TB Drug Development

Phase 2

1 8

OPC-167832

Otsuka

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Pulmonary TB

NCT06058299

Q2 2028

Phase 2Not yet recruiting

Tuberculosis, Pulmonary

NCT07672405

Clinical

Trials by Indication[1]

Tuberculosis, Pulmonary1 trial

A Phase 2b, Randomised, Multi-center, Partially Blinded Trial Assessing the Safety and Efficacy of Regimens Containing Sorfequiline, Pretomanid and Linezolid in Adults With Newly Diagnosed, Drug-sensitive, Smear Positive Pulmonary Tuberculosis

Not yet recruiting·GGlobal Alliance for TB Drug Development·Phase 2·NCT07672405·100 enrolled

Pulmonary TB1 trial

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Active, not recruiting·GGlobal Alliance for TB Drug Development·Phase 2·NCT06058299·309 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for sorfequiline. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for sorfequiline. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Global Alliance for TB Drug Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: GGlobal Alliance for TB Drug Development

sorfequiline

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Tuberculosis, Pulmonary1 trial

Pulmonary TB1 trial

References

Drug Info

Quick Facts

Related News